These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 15942626

  • 1. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
    Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL.
    Br J Cancer; 2005 Jul 11; 93(1):46-53. PubMed ID: 15942626
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB.
    J Clin Oncol; 2001 Jun 15; 19(12):2983-93. PubMed ID: 11408493
    [Abstract] [Full Text] [Related]

  • 3. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.
    Tambaro R, Greggi S, Iaffaioli RV, Rossi A, Pisano C, Manzione L, Ferrari E, Di Maio M, Iodice F, Casella G, Laurelli G, Pignata S.
    Ann Oncol; 2003 Sep 15; 14(9):1406-11. PubMed ID: 12954580
    [Abstract] [Full Text] [Related]

  • 4. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
    Duggan ST, Keating GM.
    Drugs; 2011 Dec 24; 71(18):2531-58. PubMed ID: 22141391
    [Abstract] [Full Text] [Related]

  • 5. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
    Krishna R, St-Louis M, Mayer LD.
    Int J Cancer; 2000 Jan 01; 85(1):131-41. PubMed ID: 10585596
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
    Fracasso PM, Blum KA, Tan BR, Fears CL, Bartlett NL, Arquette MA, Clark RS.
    Cancer; 2002 Nov 15; 95(10):2223-9. PubMed ID: 12412177
    [Abstract] [Full Text] [Related]

  • 7. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
    Krishna R, McIntosh N, Riggs KW, Mayer LD.
    Clin Cancer Res; 1999 Oct 15; 5(10):2939-47. PubMed ID: 10537363
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.
    Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, Aizawa T, Watanabe T, Uda Y, Tanigawara Y, Sasaki Y.
    Jpn J Cancer Res; 2001 Feb 15; 92(2):220-30. PubMed ID: 11223552
    [Abstract] [Full Text] [Related]

  • 9. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA.
    Cancer Invest; 2001 Feb 15; 19(4):424-36. PubMed ID: 11405181
    [Abstract] [Full Text] [Related]

  • 10. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ, Spencer CM.
    Drugs; 1997 Mar 15; 53(3):520-38. PubMed ID: 9074848
    [Abstract] [Full Text] [Related]

  • 11. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
    Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI.
    Ann Oncol; 2005 Dec 15; 16(12):1968-73. PubMed ID: 16126736
    [Abstract] [Full Text] [Related]

  • 12. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
    Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, Verhoef G, Dekker A, Ossenkoppele G, Ferrant C, Yin L, Gratwohl A, Kovacsovics T, Vellenga E, Capdeville R, Löwenberg B.
    Hematol J; 2000 Dec 15; 1(6):411-21. PubMed ID: 11920222
    [Abstract] [Full Text] [Related]

  • 13. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
    Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI.
    Clin Cancer Res; 2001 May 15; 7(5):1221-9. PubMed ID: 11350887
    [Abstract] [Full Text] [Related]

  • 14. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
    Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD.
    J Clin Pharmacol; 1996 Jan 15; 36(1):55-63. PubMed ID: 8932544
    [Abstract] [Full Text] [Related]

  • 15. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP.
    Clin Cancer Res; 2002 Feb 15; 8(2):413-8. PubMed ID: 11839657
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.
    Chastagner P, Devictor B, Geoerger B, Aerts I, Leblond P, Frappaz D, Gentet JC, Bracard S, André N.
    Cancer Chemother Pharmacol; 2015 Aug 15; 76(2):425-32. PubMed ID: 26115930
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998 Aug 15; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch, Androulakis N, Vamvakas L, Kalykaki A, Spiridonakou S, Kentepozidis N, Saridaki Z, Xiropoulou E, Georgoulias V.
    Oncology; 2005 Aug 15; 69(3):202-7. PubMed ID: 16127289
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
    Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP.
    J Clin Oncol; 2001 Jun 15; 19(12):2975-82. PubMed ID: 11408492
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
    Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD.
    J Clin Oncol; 1997 Feb 15; 15(2):653-9. PubMed ID: 9053490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.